Biotech / AI

🔥 Formation Bio Just Raised $600 Million to Buy the Drugs Everyone Else Gave Up On

Formation Bio unveiled a $600M fund to buy or license stalled Phase 1-2 drugs and push them through trials with AI.

By Tech Arcade··5 min read

Formation Bio Just Raised $600 Million to Buy the Drugs Everyone Else Gave Up On — Tech Arcade
Photo: Testalize.me / Unsplash

Most AI drug startups chase the glamorous part: designing new molecules from scratch, letting the model dream up a protein no chemist has seen. Formation Bio is betting the real money is in the drugs that already exist and already failed to find a home.

Let’s get the number on the table first: $600 million. That’s the size of the new fund Formation Bio unveiled on October 28 — the Formation Bio Drug Development Accelerator Fund — and its entire job is to buy or license drugs that have stalled and shove them back into clinical trials (PR Newswire).

Not drugs that flopped in patients. Drugs that ran out of cash, lost a champion, or got orphaned when a biotech pivoted. The science was promising; the money wasn’t there.

The thesis is blunt: the bottleneck in modern pharma isn’t ideas, it’s the brutal, expensive slog of proving a drug works in humans — and Formation thinks AI plus a pile of patient capital can clear that slog faster than anyone else.

🧠 Why This Matters

The drug industry has a graveyard problem. Promising compounds get shelved all the time — not because they’re bad, but because the company holding them ran into a cash crunch, a strategy change, or a portfolio reshuffle. Those assets just sit there.

Formation Bio wants to be the buyer that goes shopping in that graveyard. The $600 million fund is structured to acquire or license 10 to 15 drug programs over the next three to five years, focusing on Phase 1 and Phase 2 candidates — early enough to be cheap, late enough to have real human data behind them (PR Newswire).

Here’s CEO Ben Liu on the core problem, which is refreshingly un-hyped:

“The fundamental bottleneck is how do you show they work in the clinic.”

That’s the whole pitch in one line. Discovery gets the headlines. Trials get the bodies, the years, and the budget.

📊 Deep Dive

Formation Bio isn’t a newcomer playing dress-up. It was founded in 2016 as TrialSpark, rebranded, and has since raised roughly $615 million in total — including a $372 million Series D in June 2024 — at a valuation of about $1.8 billion (Forbes, Yahoo Finance). Its backer list reads like a Silicon Valley guest book: Andreessen Horowitz, Sequoia, Thrive Capital, John Doerr, and Sam Altman.

The new fund is a different animal from the company’s own venture rounds. Here’s how it’s built, piece by piece:

  • Size: $600 million in capital commitments — Formation’s first external fund
  • Target: stalled Phase 1 and Phase 2 drug programs, not fresh discovery
  • Volume: 10 to 15 programs over three to five years
  • Structure: each drug gets parked in its own standalone company, keeping the economics separate
  • Backers of the fund: research foundations, institutional endowments, hospitals, and philanthropic organizations — not the usual venture crowd
  • Who runs the science: Michael Ehlers, hired as chief scientific officer, a veteran of Biogen and Pfizer who has helped get six drugs approved (Forbes)

The standalone-company trick is the clever bit. Because each acquired drug sits in its own entity, the original developer, the fund’s investors, and Formation itself can all share in the upside if a drug makes it — without anyone having to sell a stake in the parent company. Liu’s framing:

“The Fund creates paths to liquidity without selling the parent company.”

Translation: Formation can take a lot of swings, spread the risk across separate bets, and keep its own cap table clean. The fund sits off to the side, Formation acts as general partner through a wholly owned subsidiary, and it has thrown in its own cash alongside the outside investors.

As for what’s actually in the pipeline: the fund has already licensed two drugs, which the company won’t name yet. Before the fund existed, Formation had bought or licensed five, including a knee osteoarthritis treatment and an ulcerative colitis therapy. The hunting grounds now include muscle and bone health, ophthalmology, and neurological and psychiatric disease.

⚠️ The Catch

Buying cheap, early-stage drugs is cheap for a reason. Most drug candidates that enter human trials never reach the market, and Phase 1 and Phase 2 assets are exactly where a lot of that failure happens. Formation is deliberately wading into the riskiest water and betting its AI-and-operations machine can improve the odds.

So far, that’s a bet, not a result. The two licensed drugs are unnamed and unproven. The AI-runs-trials-faster claim is the entire reason the company exists, and it still hasn’t produced an approved drug of its own to point to. Ehlers called the fund “a meaningful next step for real-world application of AI” — note the words next step, not finished product.

There’s also the small matter of patience. Drug trials run on biology’s clock, not a software release schedule. A fund promising 10 to 15 programs over three to five years is signing up for a long, expensive wait before anyone knows whether the model worked.

🎯 What Happens Next

Watch for two things. First, names — the moment Formation discloses which stalled drugs it actually bought, you can judge whether it’s finding genuine hidden gems or just the stuff nobody else wanted. Second, trial readouts. If an AI-accelerated program hits a Phase 2 milestone noticeably faster or cheaper than the industry norm, the whole “capital bottleneck” thesis gets real evidence behind it.

Expect more of these structures, too. An off-to-the-side fund that lets a startup take many shots without diluting itself is an appealing template, and if it works, rivals will copy it fast.

🧩 Bigger Picture

The AI drug race has spent years obsessed with the front door — generating novel molecules, folding proteins, designing the next blockbuster from zero. Formation Bio is quietly walking around to the back, where thousands of half-finished drugs are gathering dust because the money dried up before the science got its fair shot.

If the model works, the most valuable thing AI does for medicine might not be inventing new drugs at all. It might be finishing the ones we already started.

The hard part of a drug was never the idea. It was surviving long enough to prove it.

Sources

❓ Quick answers

How much is Formation Bio's new drug fund?

It is $600 million in capital commitments, announced Oct 28, 2026 as the Formation Bio Drug Development Accelerator Fund (PR Newswire).

What does the Formation Bio fund actually do?

It buys or licenses stalled Phase 1 and Phase 2 drug programs and pushes them through clinical trials using AI, targeting 10-15 programs over three to five years (PR Newswire).

How much is Formation Bio worth?

About $1.8 billion; the company has raised roughly $615 million total, including a $372 million Series D in June 2024, with backers like a16z, Sequoia, Thrive, John Doerr and Sam Altman (Forbes).